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The treatment of Parkinson’s disease by transplantation of dopaminergic (DA) neurons from human embryonic mesencephalic
tissue is a promising approach.However, the origin of these cells causesmajor problems: availability and standardization of the graft.
Therefore, the generation of unlimited numbers of DA neurons from various types of stem or progenitor cells has been brought
into focus. A source for DA neuronsmight be conditionally immortalized progenitor cells.The temperature-sensitive immortalized
cell line CSM14.1 derived from the mesencephalon of an embryonic rat has been used successfully for transplantation experiments.
This cell line was analyzed by unbiased stereology of cell type specific marker proteins and 2D-gel electrophoresis followed by mass
spectrometry to characterize the differentially expressed proteome. Undifferentiated CSM14.1 cells only expressed the stem cell
marker nestin, whereas differentiated cells expressed GFAP or NeuN and tyrosine hydroxylase. An increase of the latter cells during
differentiation could be shown. By using proteomics an explanation on the protein level was found for the observed changes in cell
morphology during differentiation, when CSM14.1 cells possessed the morphology of multipolar neurons. The results obtained in
this study confirm the suitability of CSM14.1 cells as an in vitromodel for the study of neuronal and dopaminergic differentiation
in rats.
1. Introduction
Themotoric cardinal symptoms (rigor, tremor, akinesia, and
postural instability) in Parkinson’s disease (PD) are caused
by the degeneration of dopaminergic (DA) neurons. Most
of these dopaminergic neurons are located in the substantia
nigra pars compacta.The classical, symptomatic treatment of
the disease includes the use of pharmaceuticals like L-DOPA
or the more invasive deep brain stimulation. Furthermore,
over the last three decades the concept of cell replacement has
been brought into focus. In various clinical trials postmitotic
DA neurons from human embryonic mesencephalic tissue
have demonstrated to be the most prospective cells for
transplantation in human PD brains [1, 2].
However, the origin of these cells from human embryos
causes their major limitation concerning tissue availability
and standardization of the graft. Therefore, to establish cell
replacement therapy as an available therapeutic option for
many PD patients, other ways to generate DA neurons in
unlimited number and consistent quality have to be found.
Over the last years various protocols for the production of
DAneurons, for example, from embryonic stem cells or foetal
neuronal stem cells, have been used. Another approach is
the generation of DA neurons via induced pluripotent stem
cells [3]. However, the use of conditionally immortalized
progenitor cells is also a promising approach due to nearly
unlimited access of material [4].
The temperature-sensitive immortalized mesencephalic
progenitor cell line CSM14.1 derived from a 14-day-old rat
embryo [5–8] differentiates in vitro in tyrosine hydroxy-
lase (TH) and aldehyde-dehydrogenase-2 (ALD2)-expressing
neurons. Undifferentiated CSM14.1 cells also contain the
stem cell marker nestin and also the expression of Nurr-
1—a member of the superfamily of orphan nuclear retinoic
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acid receptors—which plays an important role in the dif-
ferentiation of dopaminergic neurons, has been described
[9]. During differentiation the cells also show a change
from an epithelial fibroblast-like phenotype to a morphology
resemblingmultipolar neurons. After transplantation into the
striatum of neonatal hemiparkinsonian rats the differentia-
tion into TH-expressing cells and an improvement inmotoric
function could be demonstrated [10].
In contrast to the above mentioned results concerning
the characterization of CSM14.1 cells in vitro obtained by
using immunocytochemistry andwestern blotting, by the use
of proteomic approaches important issues such as protein
amount, protein stability, subcellular localization of proteins,
posttranslational modifications, and protein-protein inter-
actions can be elucidated [11]. Therefore, in this study we
investigated the ability of the cell line CSM14.1 to function as
a model for the neuronal and dopaminergic differentiation
in rats by combining unbiased stereological evaluation of
cell type specific marker proteins with 2D-gel electrophoresis
followed by mass spectroscopy to analyze the differentially
expressed proteome.
2. Material and Methods
2.1. Cell Culture and Immunocytochemistry. Immortalized
CSM14.1 cells [5] were cultivated and expanded as described
byHaas andWree [9] in DMEM supplemented with 10% fetal
calf serum (FCS), 100UnitsmL−1 penicillin, and 100 𝜇gmL−1
streptomycin in a humidified incubator (95% air, 5% CO
2
,
33∘C). Cell passage was done every third day. To induce
differentiation the amount of FCS was reduced to 1% and the
temperature was risen to 39∘C—nonpermissive temperature
[12, 13]. The media was routinely changed every third day.
All cell tissue reagents were obtained from Gibco Invitrogen
Corporation, Carlsbad, CA, USA.
2.2. For Immunocytochemistry CSM14.1 Cells Were Cultivated
in 24 Well Plates. Undifferentiated cells and cells after 14
days and 28 days of differentiation, respectively, (see above)
were washed with 0.1M PBS (pH 7.4) and fixed in 3.7%
paraformaldehyde solution (solved in 0.1M PBS, pH 7.4) for a
minimum of one hour. After three washes with PBS (pH 7.4)
the cells were preincubated for 60 minutes in PBS (pH 7.4)
containing 3% bovine serum albumine (BSA), 0.025% Triton
X-100, and 3%normal horse serum (NHS) to block unspecific
binding sites.
Incubation with the primary antibodies directed against
the neural stem cell protein (nestin, mouse monoclonal,
1:500, BD Biosciences, San Jose, CA, USA), glial fibrillary
acidic protein (GFAP, mouse monoclonal, 1:400, Sigma-
Aldrich Corporation, St. Louis, MO, USA), neuronal nuclei
antigen (NeuN, mouse monoclonal, 1:1000, Chemicon, Bil-
lerica, MA, USA), and tyrosine hydroxylase (TH clone 2,
mouse monoclonal, 1:500, Sigma-Aldrich) dissolved in 0.1M
PBS containing 0.025% Triton X-100 and 1% BSA was done
at 4∘C overnight. For each time point and antibody four
independent experiments were performed. After washing
for three times with PBS (pH 7.4) the cells were incubated
with the Cy3-conjugated secondary antibody (Donkey anti-
mouse IgG + IgM, 1:500, Jackson ImmunoResearch Labo-
ratories, Inc., West Grove, PA, USA) dissolved similar to
primary antibodies at 4∘C overnight. For cell counting the
cell nuclei were stained with 4.6-diamidino-2-phenylindol
dihydrocloride (DAPI, Carl RothGmbH+Co.KG,Karlsruhe,
Germany).
For the various cell type specific markers four different
culture wells per marker were examined for each of the three
different groups, leading to the examination of 48 cell culture
wells.
2.3. Cell Counting and Statistics. Microphotography and cell
counting were performed with an Olympus BX 51 micro-
scope and the Stereo Investigator v8.0 (MicroBrightField
Bioscience, Vermont, USA) software. Cells were counted
using the 10x objective and an unbiased counting frame
[14]. A characteristic point of a cell was applied to decide
if the cell should be counted. Hereby the cell nuclei were
chosen. Quantification was performed in region of the whole
cell culture well that was placed under the circular cover
slip (diameter 1.2 cm). Counting frames had a dimension of
500 × 500 𝜇m2 and a distance to each other of 1000 𝜇m.
A systematic random sampling, controlled by the Stereo
Investigator software, ensured that frame regions were not
double counted. An average of about 500 cells per culture
well were examined during the counting procedure.The Chi-
Quadrat test and Fisher’s exact test were used (SPSS v11.01,
SPSS Inc. IBMCompanyHeadquarters, Chicago, IL, USA) to
compare cell counts.
2.4. Proteomics. For proteomics CSM14.1 cells were culti-
vated and differentiated in tissue culture dishes as described
above. After removal of the culture medium undifferenti-
ated cells (day 0) and cells after 28 days of differentiation
(day 28) were washed twice with ice cold PBS (pH 7.4).
Afterwards the cells were mechanically removed from the
bottom of the tissue culture dishes in 1mL ice cold PBS
each. The cell suspension was fractionated in 1.5mL reaction
tubes which underwent centrifugation for 5min at 4∘C and
5000 rpm (Heraeus Megafuge 1.0R, Thermo Fisher Scien-
tific Inc., Waltham, MA, USA, Rotor 3041). The remaining
mass of each cell pellet was approximately 150mg. After
freezing at −80∘C (9 × probe mass (mg)) 𝜇L lysis buffer
(containing 7M urea (Sigma-Aldrich), 2M thiourea (Sigma-
Aldrich), 70mM DTT (Sigma-Aldrich), 4%w/v CHAPS
(Sigma-Aldrich), 0.5% ampholyte high resolution ph 3–10
(Sigma-Aldrich)), (0.4 × mass probe (mg)) 𝜇L Complete
(Roche Diagnostics GmbH, Basel, Swiss), (0.1 × probe mass
(mg))𝜇LPMSF (Sigma-Aldrich), and (0.1×probemass (mg))
𝜇L PepA (Sigma-Aldrich) were added.The tubes were quickly
frozen in liquid nitrogen, warmed up at room temperature,
sonificated in an ice cold ultrasound bath for 5min and then
centrifuged for 20min at 4∘Cand 15.000 rpm (Megafuge 1.0R,
Rotor 3041). Protein concentration was measured using a
Bradford solution by Sigma-Aldrich. Sample aliquots were
stored at −80∘C.
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The isoelectric focussing (IEF) procedure was performed
with 18 cm nonlinear Immobiline DryStrip pH 3–10 (GE
Healthcare Bio-Sciences AB, Uppsala, Sweden) which was
rehydrated at 20∘C for 20 h. Each stripwas loadedwith 500𝜇g
protein using cup-loading technology at anode and cathode.
Electric focussing was performed with a Protean IEF Cell
(Bio-Rad Laboratories, Inc., Hercules, CA, USA) at 8000V
resulting in approximately 100 kVh. Furthermore, IEF strips
were incubated with equilibration buffer containing 1.5M
Tris-HCl pH 8.8, 6M urea, 30% glycerol, 2% SDS, and
64.8mM DDT for 30min followed by a second incubation
with the same buffer containing 20mM 2-VP instead of
DTT. Second dimension was carried out on 12% SDS gels
using a Protean Plus Dodeca Cell (BioRad) at 125V and
12∘C for approximately 16 hrs. Afterwards gels were fixedwith
45% methanol and 1% acetic acid for 24 hrs. Staining was
performed using Brilliant-Blue Coomassie G250 (Carl Roth).
For digitization at 300 dpi/12 bit a Heidelberg Nexscan F4100
(Heidelberger Druckmaschinen, Heidelberg, Germany) was
used. For further analysis the program Progenesis PG 200
version 2006 (Nonlinear Dynamics Ltd., Newcastle, Great
Britain) was applied.
Image analysis was performed using Progenesis PG200
Version 2006 (Nonlinear Dynamics Ltd., Newcastle upon
Tyne, U.K.). Two groups of experimental gels (6 gels from
day 0 and 6 gels from day 28) were registered to a reference
gel chosen from day 0 gels. Spots showing a 2.5-fold larger or
lower spot volume in 5 or 6 different gels of each group were
considered up- or downregulated. Absent spots were defined
as spots found in 5 or 6 gels of the day 28 group and not found
in any gel of the day 0 group and the reference gel.
Spot picking, in-gel enzymatic digestion of proteins, and
MALDI-TOF-MS analysis were performed as described cir-
cumstantially in Lessner et al. [15]. For protein identification
the UniProtKB/Swiss-Prot database was used.
3. Results
3.1. Immunocytochemistry and Cell Counting. The type VI
intermediate filament (IF) protein nestin is a widely-used
marker for neuronal progenitor cells. As compared to pre-
vious studies [9, 16], here we also demonstrate that a large
portion of undifferentiated CSM14.1 cells was immunoreac-
tive for nestin (Figure 1(a)) and that during differentiation the
number of nestin-immunoreactive cells decreased (Figures
1(b), 1(c), and 2(a)). The results of unbiased stereological cell
counting revealed a significant decrease of nestin-containing
cells from 38.74% (±0.62) at day zero to 11.46% (±0.53) at 14
days of differentiation (𝑃 < 0.001). The number of nestin-
immunoreactive cells after 28 days of differentiation was
15.09% (±3.72) (Figure 2(a)) and was significantly lower than
at day zero (𝑃 < 0.001) but did not significantly differ from
day 14 (Figure 2).
GFAP, a member of type III IF proteins, is known
as an important and obligatory protein of astrocytes [17].
Undifferentiated CSM14.1 cells were not immunoreactive for
GFAP in this study (Figure 1(d)), whereas after 14 and 28
days of differentiation, respectively, an increase in GFAP-
immunoreactivity was observed (Figures 1(e) and 1(f)). The
amount of GFAP-containing cells 14 days after differen-
tiation was 18.72% (±2.54) and this number increased to
19.66% (±2.04) 28 days after differentiation (Figure 2(b)).
At both time points of differentiation the number of GFAP-
containing cells was significantly different (𝑃 < 0.001) from
the starting point but not significantly different between
14 and 28 days of differentiation. However, an increase in
fluorescence intensity in GFAP-immunoreactive cells over
time was observed indicating higher contents of GFAP after
28 days of differentiation.
A commonly used marker for postmitotic nerve cells is
the neuronal nuclear protein NeuN with unknown function.
In undifferentiated CSM14.1 cells the expression of NeuN
could not be detected (Figure 1(g)) but its content in the
CSM14.1 cells increased constantly during differentiation
(Figures 1(h) and 1(i)). After 14 days of differentiation the
number of 27.56% (±3.31) of cells was immunoreactive for
NeuN (Figure 2(c)) and a further increase up to 64.06%
(±2.74) after 28 days of differentiation could be shown
(Figures 1(i) and 2(c)). At both differentiation time points
the NeuN-immunoreactive cell numbers were significantly
higher compared to the starting point (𝑃 < 0.001) and the
increase between 14 and 28 days of differentiation was also
significantly different (𝑃 < 0.001).
A similar result was also found for TH, the pacemaker
enzyme of dopamine biosynthesis, which is a widely used
protein to identify dopaminergic neurons. Undifferentiated
CSM14.1 cells did not show any immunoreactivity for TH
(Figure 1(j)). During differentiation TH was detectable after
14 days (Figure 1(k)) and the number of TH-containing cells
increased after 28 days (Figure 1(l)). Like for the GFAP
immunofluorescence signal, the TH containing cells seemed
to contain more of the epitope due to an increase of fluores-
cence intensity. After 14 days of cultivation at 39∘C 12.07%
(±1.71) of the cells were TH-positive and a significant increase
up to 55.69% (±2.92) after 28 days of differentiation was
detected (Figure 2(d)). At both differentiation time points the
TH-immunoreactive cell numbers were significantly higher
compared to the starting point (𝑃 < 0.001) and the
increase between 14 and 28 days of differentiation was also
significantly different (𝑃 < 0.001).
3.2. Proteomics. In the reference gel 506 spots could be
detected and 70.2% (±5.3) of the spots from the experimental
gels at day 0 could be matched onto the reference gel (Fig-
ure 3(a)). In contrast, only 49.2% (±3.37) of the spots from the
experimental gels at day 28 found amatch on the reference gel
(Figure 3(b)). Using the selection criteria as shown above, 27
spots were found upregulated in differentiated CSM14.1 cells,
24 spots downregulated, and 46 spots were detected as absent
(i.e., only found in differentiated CSM14.1 cells). ViaMALDI-
TOFMS analysis 64 proteins could be identified (Table 1).The
majority of proteins only detected in differentiated CSM14.1
cells (Figure 4(a)) were classified as regulating proteins
(17%), chaperons (17%), and proteins against oxidative stress
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Figure 1: Results from ICC-staining of CSM14.1 cells during differentiation are shown. Images do not represent counting frame pictures
and the numbers and distribution of immunoreactive cells should not be compared with the stereological results. However, morphological
changes and different contents of cell type specific markers are recognizable. In the first row ((a), (b), (c)) images of staining against nestin
(red) and DAPI (blue) are merged. A significant decrease of nestin-expression between undifferentiated cells (a) and cells that differentiated
for 14 days (b) or 28 days (c) could be observed. In the second row ((d), (e), (f)) images of staining against GFAP (red) and DAPI (blue)
are merged. Undifferentiated cells do not express GFAP (d). After 14 days of differentiation GFAP-positive cells could be detected (d) and
an increase of positive cells could be shown after 28 days of differentiation (f). In the third row ((g), (h), (i)) images of staining against the
neuronal marker NeuN (red) and DAPI (blue) are merged. No NeuN-positive cells could be detected in undifferentiated cells (g), whereas
NeuN expressing cells could be found after 14 days of differentiation (h) and an increase in NeuN-positive cells could be observed after 28
days of differentiation (i). In the fourth row ((j), (k), (l)) images of staining against TH (red) and DAPI (blue) are merged. Undifferentiated
cells do not express TH (j). TH-positive cells could be found after 14 days of differentiation (k) and an increase of TH-expressing cells was
observed after 28 days of differentiation (l). Scale bars = 200𝜇m ((a)–(l)).
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Figure 2: Results from unbiased cell counting are shown. In undifferentiated cells an amount of 38.74% (±0.62) nestin-positive cells (a) was
found. During differentiation a significant decrease in the amount of positive cells could be observed. After 14 days 11.46% (±0.53) and after 28
days 15.09% (±3.72) of all cells were nestin-positive. GFAP (b) could not be detected in undifferentiated cells. After 14 days of differentiation
18.72% (±2.54) of all cells were GFAP-immunoreactive. The amount of GFAP-immunoreactive cells did not change significantly after 28
days of differentiation up to 19.66% (±2.04). Undifferentiated cells did not contain NeuN (c). After 14 days of differentiation 27.56% (±3.31)
were NeuN-positive and a significant increase up to 64.06% (±2.74) could be observed after 28 days of differentiation. TH (d) could not be
found in undifferentiated cells, but a significant increase in the amount of TH-immunoreactive cells from 12.07% (±1.71) after 14 days up to
55.69% (±2.92) after 28 days of differentiation could be observed. Error bars show SEM. ∗Significant difference from the respective time point;
𝑃 < 0.001. For statistical analysis Chi-Quadrat test and Fisher’s exact test were applied.
(17%). Upregulated proteins (Figure 4(b)) belonged primar-
ily to structural proteins (31%), regulating proteins (13%),
chaperons (13%), and proteins of energy metabolism (13%).
Proteins with a lower expression in differentiated CSM14.1
cells (Figure 4(c))were classified as regulating proteins (40%),
proteins associated with transcription (20%) and translation
(20%), and carbohydrate metabolism (20%).
4. Discussion
4.1. Immunocytochemistry and Cell Counting. As a parallel
approach by characterising the changes in the proteome of
differentiating CSM14.1 cells we used various cell type specific
antibodies to document the morphological and phenotyp-
ical alterations over time. Hereby we also used unbiased
stereology to quantify the differences in immunoreactive
cell numbers. Undifferentiated CSM14.1 cells were known to
express the stem cell marker nestin [9]. In this study we
were able to show that only 38.74% (±0.62) of all cells are
immunoreactive for nestin which is a contrary finding to
the clonal origin of the cell line [5] and might be explained
by proliferating cells in different phases of the cell cycle.
After 28 days of differentiation 15.09% (±3.72) of all cells still
express nestin which indicates that differentiationmay not be
complete in all cells at this time point [18]. In this study GFAP
could not be detected via immunocytochemistry in undiffer-
entiated CSM14.1 cells which is a contrary finding to Vernon
and Griffin [16], who demonstrated immunoreactivity in
western blots and immunocytochemistry by using polyclonal
antibodies against GFAP. Moreover, Vernon and Griffin [16]
showed, after an initial increase of GFAP after two weeks of
differentiation, a constant decrease below the GFAP content
of undifferentiated cells. Our findings, by using amonoclonal
primary antibody directed against GFAP, indicate that in
undifferentiated CSM14.1 cells GFAP is not detectable but
that under differentiation conditions about 20 percent of the
cells contain GFAP.This discrepancy between the findings of
Vernon and Griffin and our recent results could be explained
by the use of polyclonal antibodies. The use of polyclonal
antibodies in vivo and also in vitro is problematic due to the
cause of the unspecific cross reactivity of antibodies produced
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Figure 3: Comparison of 2 DE images of undifferentiated CSM14.1 cells (a) and of CSM14.1 cells after 28 days of differentiation (b). For spot
visualization Coomassie-staining was used. Two groups of experimental gels (6 gels from day 0 and 6 gels from day 28) were registered to a
reference gel chosen fromday 0 gels. Spots showing a 2.5-fold larger or lower spot volume in 5 or 6 different gels of each groupwere considered
up- or downregulated. Absent spots were defined as spots found in 5 or 6 gels of the day 28 group and not found in any gel of the day 0 group
and the reference gel. In the reference gel 506 spots could be detected and 70.2% (±5.3) of the spots from the experimental gels day 0 could be
matched onto the reference gel. In contrast, only 49.2% (±3.37) of the spots from the experimental gels day 28 found a match on the reference
gel. Using the selection criteria as shown above, 27 spots were found upregulated in differentiated CSM14.1 cells, 24 spots downregulated, and
46 spots were detected as absent (i.e., only found in differentiated CSM14.1 cells). Via MALDI-TOF analysis 64 proteins could be identified.
from the serum of immunized animals [19]. The increase of
neuronal markers and TH in differentiating CSM14.1 cells is
in line with our previous studies [9] and with findings from
other groups [16, 20].
Vernon and Griffin [16] showed that differentiated
CSM14.1 cells express the neuron-specific, soluble nuclear
protein NeuN at a significantly higher degree than undif-
ferentiated CSM14.1 cells. In vivo NeuN-positive CSM14.1
cells were detectable after transplantation into the striatum
of neonatal rats [10] or into the substantia nigra of adult
hemiparkinsonian rats [21]. Assuming that CSM14.1 cells at
permissive culture conditions (33∘C, 10% FCS) are undif-
ferentiated, these cells should not show immunoreactivity
against NeuN, which could be demonstrated in the present
study. Moreover, after 14 days of differentiation 27.56% of all
cells were NeuN-positive. After 28 days of differentiation,
there was a significant increase in immunoreactivity for
NeuN up to 64.06%. These results point to an increasing dif-
ferentiation of CSM14.1 cells into neurons over the observed
time period.
In differentiated CSM14.1 cells TH, the pacemaker
enzyme of dopamine biosynthesis, could be detected by west-
ern blotting [9, 16] and Vernon and Griffin [16] also achieved
this by immunocytochemistry using a polyclonal antibody. In
both works, a weak immunoreactivity for TH was also found
in undifferentiated CSM14.1 cells by immunocytochemistry
and western blots. In vivo TH-positive CSM14.1 cells were
only detected after intrastriatal transplantation in neonatal
rats [10].
In this study undifferentiated CSM14.1 cells showed no
immunoreactivity for TH. This result is congruent with the
results of NeuN andGFAP as shown above.There is also a sig-
nificant increase in the amount of TH immunoreactive cells
over the observed time period (12.07% at day 14 and 55.69%
at day 28). The differences between our recent findings and
the observations made by Vernon and Griffin in 2005 [16]
might be explained by the use of a monoclonal antibody in
our study. The detection of TH alone does not characterize a
cell as dopaminergic, because dopamine can also be metabo-
lized to the catecholamines epinephrine and norepinephrine
[22, 23]. However, the expression of the enzyme ALDH2
by differentiated CSM14.1 cells [9] makes a dopaminergic
differentiation most likely, because ALDH2 could be used for
the detection of differentiated dopaminergic cells [24–26].
Nevertheless, in the future the expression of the dopamine
transporter in CSM14.1 cells or the content of dopamine itself
in culture of differentiated CSM14.1 cells should be proofed.
4.2. Proteomics. In this study it was shown that the expression
of the protein annexin A5 by the cell line CSM14.1 between
day 0 (undifferentiated cells) and day 28 (differentiated cells)
is upregulated. The same result has also been shown for
the neuronal progenitor cell line ST14A derived from the
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Table 1: Differentially expressed proteins in CSM14.1 cells after 28 days of differentiation.
Acc. No. Entry name Protein name Expression Score MW pI Qm Sc Mixed
Structural proteins
Q6AYZ1 TBA1C RAT Tubulin alpha 1C-chain Absent 56 50590 4.96 4 11 −
P31000 VIME RAT Vimentin Up 205 53757 5.06 24 36 −
P70615 LMNB1 RAT Lamin-B1 Up 188 66794 5.16 21 33 −
P60711 ACTB RAT Actin, cytoplasmic 1 Up 110 42052 5.29 9 25 −
Q4V7C7 ARP3 RAT Actin related protein 3 Up 168 47783 5.61 15 36 −
P85108 TBB2A RAT Tubulin beta 2A chain Up 92 50274 4.78 14 40 +
P48679 LMNA RAT Lamin-A Landmark 401 74564 6.54 48 51 −
Q63610 TPM3 RAT Tropomyosin-alpha 3 chain Landmark 202 29217 4.75 18 43 −
P09495 TPM4 RAT Tropomyosin-alpha 4 chain Landmark 253 28549 4.66 19 47 −
Regulating proteins
Q5BKC9 NGEF RAT Ephexin-1 Absent 55 81527 5.85 6 9 −
P62142 PP1B RAT Serine/threonine-protein phosphatasePP1-beta catalytic subunit Absent 66 37961 5.84 5 19
−
O35763 MOES RAT Moesin Absent 88 67868 6.16 10 16 −
P14668 ANXA5 RAT Annexin A5 Up 288 35779 4.93 20 54 −
Q68FP1 GELS RAT Gelsolin Up 227 86413 5.76 24 31 −
O35814 STIP1 RAT Stress induced phosphoprotein 1 Down 160 63158 6.4 14 22 −
B3GNI6 SEP11 RAT Septin-11 Down 102 50005 6.24 8 21 −
P38983 RSSA RAT
40S ribosomal protein SA, laminin
receptor 1, LRP/LR; laminin-binding
protein precursor p40
Down 51 32917 4.8 4 17 −
P85515 ACTZ RAT Alpha-centractin Down 158 42701 6.19 11 40 −
Q99MZ8 LASP1 RAT Lim and SH3 domain protein 1 Landmark 126 30351 6.61 9 28 −
Transport proteins
Q9Z2L0 VDAC1 RAT Voltage dependent anion selectivechannel protein 1 Absent 61 30851 8.62 4 19
−
P02793 FRIL1 RAT Ferritin light chain 1 Absent 140 20793 5.99 11 58 −
Chaperones
Q5XHZ0 TRAP1 RAT Heat shock protein 75 kDa,mitochondrial Absent 118 80639 6.56 12 18
−
P28480 TCPA RAT T-complex protein 1 subunit alpha Absent 115 60835 5.86 9 17 −
P52555 ERP29 RAT Endoplasmic reticulum protein ERp29 Absent 127 28614 6.23 8 31 −
Q66HD0 ENPL RAT Endoplasmin, heat shock protein90 kDa beta member 1 Up 190 92998 4.72 25 31
−
P06761 GRP78 RAT 78 kDa glucose-regulated protein, heatshock 70 kDa protein 5 Up 307 72473 5.07 38 56
−
P18418 CALR RAT Calreticulin Landmark 192 48137 4.33 18 46 −
P63018 HSP7C RAT Heat shock cognate 71 kDa protein Landmark 157 71055 5.37 22 39 +
P63039 CH60 RAT 60 kDa heat shock protein,mitochondrial Landmark 200 61088 5.91 20 42
−
P48721 GRP75 RAT Stress 70 protein Landmark 161 74097 5.97 25 41 +
Q68FQ0 TCPE RAT T-complex protein 1 subunit epsilon Landmark 119 59955 5.51 18 28 −
Apoptosis
Q9QZA2 PDC6I-RAT Programmed cell death 6-interactingprotein Landmark 299 97141 6.15 28 32
−
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Table 1: Continued.
Acc. No. Entry name Protein name Expression Score MW pI Qm Sc Mixed
Enzymes
Energy metabolism
P10719 ATPB RAT ATP synthase subunit beta,mitochondrial Absent 146 56318 5.19 24 56
+
P50516 VATA MOUSE Vacuolar ATP synthase catalyticsubunit A Up 196 68625 5.42 23 36
−
P62815 VATB2 RAT Vacuolar ATP synthase subunit B,brain isoform Up 118 56857 5.57 13 28
–
P13803 ETFA RAT Electron transfer flavoprotein subunitalpha, mitochondrial Landmark 49 35272 8.62 4 13
–
Carbohydrate metabolism
P11980 KPYM RAT Pyruvate kinase isoenzyme M1/M2 Absent 175 58294 6.63 15 25 –
O88989 MDHC RAT Malate dehydrogenase, cytoplasmic Down 69 36631 6.16 5 14 –
P07943 ALDR RAT Aldose reductase Down 103 36230 6.26 10 26 –
P04797 G3P RAT Glyceraldehyde-3-phosphatedehydrogenase Landmark 111 36090 8.14 9 31
–
P04764 ENOA RAT Alpha enolase Landmark 233 47440 6.16 24 58 –
Amino acid metabolism
P0C2X9 AL4A1 RAT Delta-1-pyrroline-5-carboxylatedehydrogenase, mitochondrial Absent 166 62286 7.14 13 25
–
Q01205 ODO2 RAT
Dihydrolipoyllysine-residue
succinyltransferase component of
2-oxoglutarate dehydrogenase complex
Absent 84 49236 8.89 9 21 –
Q9JLJ3 AL9A1 RAT 4-trimethylaminobutyraldehydedehydrogenase Up 69 54530 6.57 9 21
–
P10860 DHE3 RAT Glutamate dehydrogenase 1,mitochondrial Landmark 192 61719 8.05 27 36
–
Fatty acid metabolism
P35571 GPDM RAT Glycerol-3-phosphate dehydrogenase,mitochondrial Absent 123 81549 6.18 12 19
–
P15650 ACADL RAT Long-chain specific acyl-CoAdehydrogenase Up 90 48242 7.63 10 18
–
Proteins against oxidative stress
P07632 SODC RAT Superoxide dismutase [Cu-Zn] Absent 134 16073 5.88 8 48 –
Q63081 PDIA6 RAT Protein disulfide isomerase A6 Absent 109 48542 5 8 23 –
Q8R4A1 ERO1A RAT ERO1-like protein alpha Absent 92 54839 5.83 7 19 –
P35704 PRDX2 RAT Peroxiredoxin 2 Landmark 91 21941 5.34 7 31 –
P11598 PDIA3 RAT Protein disulfide isomerase 3 Landmark 320 57044 5.88 33 56 –
P54001 P4HA1 RAT Prolyl 4-hydroxylase subunit alpha-1 Landmark 237 61202 5.63 20 36 –
Proteasom, ubiquitin system
Q9JHW0 PSB7 RAT Proteasome subunit beta type-7 Absent 61 30250 8.13 5 12 –
Q6AXR4 HEXB RAT Beta-hexosaminidase subunit beta Up 92 61888 8.02 11 23 +
Signal transduction
P62260 1433E RAT 14-3-3 Protein epsilon Landmark 127 29326 4.63 13 48 +
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Table 1: Continued.
Acc. No. Entry name Protein name Expression Score MW pI Qm Sc Mixed
Transcription
Q8VHV7 HNRH1 RAT Heterogeneous nuclearribonucleoprotein H Up 72 49442 5.7 11 28
–
P60123 RUVB1 RAT RuvB like 1, 49 kDa TATA box-bindingprotein-interacting protein Down 88 50524 6.02 6 19
–
Q9JMJ4 PRP19 RAT Pre-mRNA-processing factor 19 Down 129 55661 6.14 13 28 –
Translation
Q4KM49 SYYC RAT Tyrosyl-tRNA synthetase Down 175 59420 6.57 16 29 –
P38983 RSSA RAT
40S ribosomal protein SA, laminin
receptor 1, LRP/LR; laminin-binding
protein precursor p40
Down 51 32917 4.8 4 17 –
P05197 EF2 RAT Elongation factor 2 Landmark 135 96192 6.41 18 22 –
Q6P9U8 EIF3H RAT Eukaryotic translation initiation factor3 subunit H Landmark 132 40051 6.2 10 36
–
Unknown function
Q4FZT0 STML2 RAT Stomatin like protein 2 UP 85 38504 8.74 6 21 –
First column: Acc. No. (mascot identification). Second column: entry name (swiss-prot identification). Third column: protein title. Fourth column: expression
(categories: absent, up, down, landmark). Fifth column: score (mascot-score). Sixth column: MW (theoretical protein mass [Da]). Seventh column: pI
(theoretical isoelectric point). Eighth column: Qm (query matches). Ninth column: Sc (sequence covery [%]). Tenth column: mixed (mixed spot [+/−]).
striatum of a fetal rat [11]. Annexin A5 is a 35 kD protein
and was first discovered as an anticoagulant-acting protein
in blood vessels [27]. It is also called annexin-5, annexin V,
or lipocortin V (UniProtKP/Swiss-Prot). The annexins are
a superfamily of calcium ions- and phospholipid-binding
proteins with highly conserved binding domains [28–30].
Annexin I, III, and V inhibit the activity of phospholipase
A2 (PLA2) which acts as a key enzyme in inflammation
and cytotoxicity in the CNS [31]. The activated PLA2 cleaves
membrane phospholipids and leads to cell death [32]. Simul-
taneously precursor molecules of eicosanoids and platelet-
activating factor (PAF) are released, which promote the
production of reactive oxygen species. There are more than
27 isoforms of PLA2 in mammals which can be divided
into four main groups [33]: cytosolic PLA2, secretory PLA2,
calcium ion-independent PLA2, and PAF acetylhydrolases.
Especially the soluble PLA2 seems to play a key role in
neurodegenerative diseases such as Alzheimer’s disease [34],
multiple sclerosis [35, 36], PD [37, 38], and in the response to
spinal cord injuries [39].
Furthermore, it could be shown that annexin V plays an
important role as a regulator of apoptosis [40]. Apoptotic
cells display phosphatidylserine on the outer side of the cell
membrane, which serves as a signal for phagocytosis by
macrophages [41]. However this process is not only limited
solely to apoptotic cells but also occurs in the context of
nonapoptotic cell death programs [42] as well as in the aging
of red blood cells and the activation of platelets [43]. Healthy
cells prevent the exposure of phosphatidylserine on their cell
surface by energy-dependent processes. Annexin V binds
in the presence of calcium ions with high affinity to the
negatively charged phosphatidylserine [40]. Annexin A5 is
therefore used widely as a marker for the study of apoptosis
in vitro, in animal models, and even in vivo in patients with
cardiovascular disease or cancer.
Annexins I and V were also found to have neurotrophic
effects on cultured neurons [44, 45]. Han et al. [46] studied
the effects of the annexins II and V on the survival of
neurons and astrocytes in vitro. They could show that these
two proteins are essential for the survival and the growth
of neurites of developing cortical neurons, for the survival
of glial cells, and for the protection of neurons and glial
cells against peroxides and hypoxic injury. Whether this
observation is related to the inhibition of PLA2 by annexin
V has to be clarified.
In the present study, the absolute number of CSM14.1 cells
per petri dish is reduced by more than half during differenti-
ation (see also Haas et al. [21]). The observed increase in the
expression of annexinA5 during differentiation indicates that
cell death might occur by apoptosis. However, this increase
might also be explained by the previously described effect of
annexin A5 for the development and survival of neurons and
glia cells. The cell line CSM14.1 seems to be able to respond
to an elevated level of cell stress due to the change of the
environment with an increased expression of annexin A5.
Another protein with increased expression in differen-
tiated CSM14.1 cells is cytoplasmic actin, a globular protein
(G-actin), which forms in the presence of magnesium and
calcium ions amicrotubule independent cytoskeleton and is a
fundamental part of the contractile apparatus of muscle cells.
It also occurs in high concentrations in nonmuscle cells [47].
There is a dynamic equilibrium between monomeric and
polymeric (filamentous) actin (F-actin). The polymerization
is carried out at the positive end of a actin filament by
addition of ATP complexed G-actin and the cleavage of G-
actin occurs from the minus end. The structure of the actin
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Figure 4: Relative quantitative distribution of functional protein groups only detected in differentiated CSM14.1 cells (a) and of proteins with
a higher (b) or lower (c) expression compared to undifferentiated CSM14.1 cells. The majority of proteins only detected in differentiated
CSM14.1-cells (a) were classified as regulating proteins (17%), chaperons (17%), and proteins against oxidative stress (17%). Upregulated
proteins (b) belonged primarily to structural proteins (31%), regulating proteins (13%), chaperons (13%), and proteins of energy metabolism
(13%). Proteins with a lower expression in differentiated CSM14.1 cells (c) were classified as regulating proteins (40%), proteins associated
with transcription (20%) and translation (20%), and carbohydrate metabolism (20%).
filament was described by Holmes et al. [48]. Several proteins
regulate the dynamic equilibrium through the stabilization of
F-actin or the promotion of G-actin cleavage. One of these
proteins is gelsolin (86 kD) which shows in this study an
increased expression in differentiated CSM14.1 cells. It was
first isolated in macrophages from the rabbit lung [49] and
plays an important role in actin-based cell motility.
Depending on calcium ions gelsolin prevents further
actin polymerization by covering the plus ends [49–53]. On
the other hand it may encourage the formation of filaments
by binding two monomers and therefore functions as a
nucleus. The binding of phosphatidylinositol 4-phosphate
or phosphatidylinositol-4,5-bisphosphate to gelsolin solves
its binding to the plus end of the actin filament, so that a
quick attachment of further monomers to this filament is
possible [54, 55]. Gelsolin also plays an important role in the
formation of neurites by regulation of actin polymerisation.
PC12 cells that overexpress gelsolin develop longer neurites
with a greater motility than PC12 wild type cells [56].
Gelsolin seems to ensure the stability of actin filaments
[57]. Dong et al. showed that after entorhinal deafferenta-
tion of the hippocampus a significant increase of gelsolin
expression could be observed in activated microglia and
astrocytes [58]. Another protein with increased expression in
differentiated CSM14.1 cells is the 48 kD actin related protein
3 (Arp3). A complex of Arp3 and actin related protein 2
(Arp2/3) allows the formation of branched actin filaments
[59].
Physiologically associated with actin is the 68 kD pro-
tein moesin (membrane-organizing extension spike protein),
which is detectable only in differentiated CSM14.1 cells.
Moesin belongs together with ezrin and radixin to the family
of ERM (ezrin-radixin-moesin) proteins which are highly
conserved during evolution [60]. The ERM proteins play
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an important role in the formation and maintenance of
cell shape within growth and motility of cells [61, 62]. The
C-terminal domain of these proteins binds to actin [63–
66]. The N-terminal domain, called the FERM (band 4.1,
ezrin, radixin, moesin homology domain [67]) binds to
the cytoplasmic domain of numerous integral membrane
proteins. By intramolecular combination of the N- and C-
terminus an inactive conformation is created, which prevents
the binding of other proteins, such as F-actin [64]. At the C-
terminus, there is a conserved threonine residue whose phos-
phorylation results in a conformational change and allows the
association with other proteins [68]. This phosphorylation
is executed, for example, by the Rho kinase [69]. The ratio
between phosphorylated (pERM) and nonphosphorylated
ERM proteins is important for the formation of neurites by
neurons. In addition to the Rho kinase the LRRK2 (leucine-
rich repeat protein kinase 2) is of great importance.Mutations
in this enzyme are the cause of autosomal dominant forms of
PD [70, 71]. This kinase is closely related to the preservation
and the growth of neurites and therefore important for the
development of neurons [72]. It is assumed that the formation
of an axon from a neurite occurs when the stability of the
F-actin decreases and the stability of microtubules increases
[73, 74].
Taken together, proteins associated with the cytoskeleton
which are necessary for morphological differentiation (cell
processes) as well as migration in vivo after intracerebral
transplantation [10, 21] are correlated with an increase of
their differential expression. In further experiments protein
validation and interactions could be performed with regard
to the proteins detected here.
5. Conclusion
The changes in the expression pattern of the proteins dis-
cussed above are consistent with the previous findings for the
cell line CSM14.1. The increased expression of actin, gelsolin,
and Arp3 by differentiated cells and the expression of moesin
only by differentiated CSM14.1 might be related and could
be evidence for a neuronal development of these cells. These
findings are in agreement with the morphological change of
the cells during differentiation.
The detection of the proteins nestin (dimer: 198–
260 kDa), GFAP (50 kD), NeuN (46–48 kD), and TH (60–
68 kD) was not achieved with the selected differential exper-
imental setting. Thus, a direct comparison of the results of
bothmethods used in this study is not possible. Further inves-
tigation should include a proteinmapping of undifferentiated
and differentiated CSM14.1 cells to analyze spots which did
not fulfill our established criteria. A fractional analysis of
the individual cell compartments might also be a promising
approach. Especially integrated membrane proteins might
be a promising research objective in terms of neuronal and
especially dopaminergic differentiation.
The results obtained in this study confirm the suitability
of the cell line CSM14.1 as a model for the study of neuronal
and dopaminergic differentiation in rats.
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